Oncology  Conference update

ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

Prof. Shaheenah Dawood

Prof. Shaheenah Dawood

Publication Date

Jun 2024

menu

In this conference update video, Prof. Shaheenah Dawood joins us from ASCO 2024 to share her insights into new key breast cancer trial data from the DESTINY-Breast06, postMONARCH and INAVO120 trials and the potential impact on clinical practice.

 

ASCO 2024 selected breast cancer abstracts

  • Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with HR+, HER2-low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: Primary results from DESTINY-Breast06 (DB-06).
    Curigliano G, et al.
    Abstract LBA1000, ASCO 2024
  • Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
    Kalinsky K, et al.
    Abstract LBA1001, ASCO 2024
  • First-line inavolisib/placebo + palbociclib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months of adjuvant endocrine therapy completion: INAVO120 Phase 3 randomized trial additional analyses.
    Juric D, et al.
    Abstract #1003, ASCO 2024

 

Shaheenah Dawood is a Consultant medical oncologist and professor in clinical oncology in the United Arab Emirates. She trained in medical oncology at McGill University Hospitals in Canada and subspecialized in breast cancer management at MD Anderson Cancer Center. During her training she was awarded multiple scholar in training awards and ASCO merit awards. She has served as an editorial fellow at the New England Journal of medicine and has an MPH from the Harvard School of Public Health. She has over 100 papers to her credit including 50 peer review original articles, 30 review articles and 12 book chapters. She serves as a reviewer for multiple journals. She currently leads the oncology clinical trials program at Mediclinic City Hospital Dubai. She also serves as president of the Excellence in oncology summit that is held annually in Dubai and is co president of the Asia pacific breast cancer summit (ABCS) and Asia pacific gastrointestinal cancer summit (APGCS). She has also recently launched the international BRCA forum and young womens forum.

Prof. Shaheenah Dawood has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

MSD, Roche, BMS, New Bridge, Novartis, llilly , Pfizer, Caris, Merck, Jaansen, Ipsen,Astrazeneca, Zulleg Pharma
Programme summary
  • clock Duration 3 MIN
  • clock Language(s) flag
Watch the video now
Other episodes in this series
ASCO 2024 lung cancer highlights

ASCO 2024 lung cancer highlights

A conference update on lung cancer clinical trial data from ASCO
ASCO 2024 breast cancer highlights

ASCO 2024 breast cancer highlights

How could the data impact clinical practice?

 Current Episode
ASCO 2024 HCC highlights

ASCO 2024 HCC highlights

How could the latest clinical trial data impact the management of hepatocellular carcinoma?
ASCO 2024 upper GI cancer highlights

ASCO 2024 upper GI cancer highlights

Practice-changing upper GI trial data direct from ASCO 2024
Share this programme
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

other Other
Oncology 
Biomarker testing in NSCLC: patient and caregiver awareness and understanding

Findings from a global survey presented in a poster at ESMO 2024

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr. Rodrigo Paredes, Amy Moore, Anne-Marie Baird, Shani Shilo
Endorsed by
LUNGevity
Lung Cancer Europe IASLC
The Israeli Lung Cancer Foundation ISLB
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Sep 2024
PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from Bayer.
podcast Podcast
Oncology Rare diseases 
Neuroendocrine tumours (NETs) shared decision-making: Exploring the patient journey and individualising treatments

Experts
Dr Mohid S Khan, Sally Jenkins
Endorsed by
CommNETs
NANETS
Neuroendocrine Cancer UK
The Healing NET Foundation
  • download Downloadable
    Resources
  • clock 23 MIN
  • calendar Sep 2024
NET CONNECT
Educational programme supported by an Independent Educational Grant from Ipsen
conference-update Conference update
Oncology 
ESMO 2024: New data on GI, lung, HCC, breast and GU cancers

Renowned medical experts share their insights into new data presented at ESMO 2024

  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Sep 2024
COR2ED
video Video
Oncology Hemato-oncology 
Early relapsed/refractory multiple myeloma (RRMM): best practices in management

A 3-part video series on managing early RRMM from leading medical experts

Experts
Dr Elena Zamagni, Dr Fredrik Schjesvold, Dr Joseph Mikhael
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Sep 2024
LYMPHOMA & MYELOMA CONNECT
Educational programme supported by an Independent Educational Grant from Menarini Stemline Oncology.
other Other

Episode

2

of 2

episode
Oncology 
Optimising samples for biomarker testing in lung, prostate and gastric cancer

Recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Aug 2024
PRECISION ONCOLOGY CONNECT
Educational programme supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
publication Publication
Oncology 
Advancing HCC management in Asia: insights from patients and HCPs

Paper published in Journal of Gastrointestinal Cancer

Experts
Prof. Chee-Kiat Tan
  • download Downloadable
    Resources
  • clock 15 MIN
  • calendar Jul 2024
COR2ED
This educational programme is supported by an Independent Educational Grant from Roche.
Explore all programmes